XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 21 Months Ended
Jun. 30, 2021
Mar. 31, 2022
Mar. 31, 2021
Jun. 30, 2019
Mar. 31, 2022
Dec. 31, 2021
Jun. 15, 2021
Sep. 30, 2020
Collaboration And Other Agreements [Line Items]                
Revenues   $ 11,101 $ 16,881          
Common stock, par value (in dollars per share)   $ 0.01     $ 0.01 $ 0.01    
Deferred revenue, current   $ 25,562     $ 25,562 $ 20,646    
Deferred revenue, net of current portion   6,364     6,364 0    
2018 Zai Lab Agreement | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Non-refundable upfront payment       $ 25,000        
Non-refundable upfront payment, net of tax withholding       22,500        
Nonrefundable payment tax withholding       $ 2,500        
Potential development and regulatory milestone payments under agreement               $ 140,000
Development and regulatory milestones recognized         9,000      
Revenues, net of tax withholding     0          
Revenues   5,000            
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum                
Collaboration And Other Agreements [Line Items]                
Potential proceeds from royalties (percent)       20.00%        
Zai Lab Agreement, TRIDENT molecule | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Potential proceeds from royalties (percent)       10.00%        
Zai Lab Clinical Supply Agreements | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Revenues   200 $ 1,100          
2021 Zai Lab Agreements | Zai Labs                
Collaboration And Other Agreements [Line Items]                
Non-refundable upfront payment $ 25,000              
Potential development and regulatory milestone payments under agreement             $ 800,000  
Deferred revenue   16,200     $ 16,200 $ 16,100    
Revenues   $ 300            
Opt-in fee             $ 85,000  
Proceeds of stock sale 30,000              
Sales of stock purchase price (in dollars per share)             $ 31.3  
Potential commercial milestone payments under agreement             $ 600,000  
Collaborative agreement transaction price             $ 40,400  
Variable consideration recognized 5,000              
2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital                
Collaboration And Other Agreements [Line Items]                
Premium received on stock purchase $ 10,400